$ASMB
Assembly Biosciences Inc

2014 Q3 Form 10-Q Financial Statement

#000114420414050130 Filed on August 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.380M $1.410M $12.33M
YoY Change 525.42% 8.46% 1041.67%
% of Gross Profit
Research & Development $3.672M $1.096M -$140.0K
YoY Change -2.17% -68.77% -105.11%
% of Gross Profit
Depreciation & Amortization $1.602K $1.026K $10.00K
YoY Change
% of Gross Profit
Operating Expenses $3.672M $1.096M $12.19M
YoY Change -2.17% -68.77% 219.11%
Operating Profit -$11.06M -$2.506M
YoY Change 124.11% -47.88%
Interest Expense $40.00K $40.00K $50.00K
YoY Change -20.0% -33.33% 66.67%
% of Operating Profit
Other Income/Expense, Net $35.18K
YoY Change -31.37%
Pretax Income -$11.02M -$2.470M -$12.14M
YoY Change 125.82% -48.0% 220.32%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.02M -$2.469M -$12.14M
YoY Change 125.74% -48.04% 220.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.331M -$525.5K -$2.911M
COMMON SHARES
Basic Shares Outstanding 8.688M shares 23.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.90M $21.30M $27.10M
YoY Change -44.41% -36.42% 32.2%
Cash & Equivalents $17.93M $21.32M $27.06M
Short-Term Investments
Other Short-Term Assets $147.2K $171.6K $63.67K
YoY Change 9.2% -3.36% 6.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.08M $21.75M $27.12M
YoY Change -44.13% -35.4% 32.0%
LONG-TERM ASSETS
Property, Plant & Equipment $34.08K $7.399K $7.102K
YoY Change 346.59% -20.69% 3.82%
Goodwill $12.64M $0.00
YoY Change
Intangibles $30.14M $0.00
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $42.31M $7.399K $7.102K
YoY Change 554330.5% -20.69% 3.82%
TOTAL ASSETS
Total Short-Term Assets $18.08M $21.75M $27.12M
Total Long-Term Assets $42.31M $7.399K $7.102K
Total Assets $60.39M $21.76M $27.13M
YoY Change 86.6% -35.4% 31.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.000M $1.421M $2.615M
YoY Change -56.15% -33.32% 41.54%
Accrued Expenses $48.44K $23.44K
YoY Change -89.32% -97.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.049M $1.500M $2.638M
YoY Change -54.39% -42.31% -2.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.049M $1.500M $2.638M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $13.19M $1.470M $2.638M
YoY Change 469.18% -43.15% -3.91%
SHAREHOLDERS EQUITY
Retained Earnings -$129.3M -$111.7M
YoY Change
Common Stock $4.679K $4.147K
YoY Change -76.13% -67.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.20M $20.29M $24.49M
YoY Change
Total Liabilities & Shareholders Equity $60.39M $21.76M $27.13M
YoY Change 86.6% -35.4% 31.99%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q4
OPERATING ACTIVITIES
Net Income -$11.02M -$2.469M -$12.14M
YoY Change 125.74% -48.04% 220.22%
Depreciation, Depletion And Amortization $1.602K $1.026K $10.00K
YoY Change
Cash From Operating Activities -$3.870M -$2.320M -$5.400M
YoY Change -16.77% -31.36% 75.9%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $510.0K
YoY Change
Cash From Investing Activities $490.0K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 230.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.870M -2.320M -5.400M
Cash From Investing Activities 490.0K 0.000 0.000
Cash From Financing Activities 0.000 0.000 230.0K
Net Change In Cash -3.380M -2.320M -5.170M
YoY Change 168.25% -31.56% 68.4%
FREE CASH FLOW
Cash From Operating Activities -$3.870M -$2.320M -$5.400M
Capital Expenditures -$20.00K $0.00 $0.00
Free Cash Flow -$3.850M -$2.320M -$5.400M
YoY Change -17.2% -31.16% 75.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7102 USD
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3814170 shares
CY2012Q1 asmb Shelf Registration Offering Amount
ShelfRegistrationOfferingAmount
100000000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
A preferred stock was convertible into 10 common shares of the Companys common stock at any time at the holders option.
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1135000 USD
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4983126 shares
asmb Restricted Stock Expensed Percentage
RestrictedStockExpensedPercentage
0.25 pure
CY2014Q1 asmb Proceeds From Sale Of Common Stock At Net Of Offering Costs
ProceedsFromSaleOfCommonStockAtNetOfOfferingCosts
1763000 USD
CY2014Q2 asmb Shelf Registration Common Stock Offered Amount
ShelfRegistrationCommonStockOfferedAmount
10100000 USD
CY2014Q2 asmb Shelf Registration Securities Available For Issuance Number
ShelfRegistrationSecuritiesAvailableForIssuanceNumber
70000000 shares
CY2014Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
75000000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21316328 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27061268 USD
CY2014Q2 us-gaap Other Assets Current
OtherAssetsCurrent
171554 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
63672 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
21747803 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
27124940 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7399 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2614619 USD
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48435 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23435 USD
CY2014Q2 us-gaap Liabilities
Liabilities
1469788 USD
CY2013Q4 us-gaap Liabilities
Liabilities
2638054 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
172209 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
20973 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
151236 shares
CY2014Q2 asmb Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
151236 shares
CY2013Q4 asmb Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
38.85
asmb Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
33.00
CY2014Q2 asmb Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
39.65
asmb Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights
39.65
CY2014Q2 us-gaap Assets
Assets
21755202 USD
CY2013Q4 us-gaap Assets
Assets
27132042 USD
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1421353 USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
44 USD
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
4679 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
4147 USD
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
138174448 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135844320 USD
CY2014Q2 asmb Common Stock Value Issuable
CommonStockValueIssuable
368750 USD
CY2013Q4 asmb Common Stock Value Issuable
CommonStockValueIssuable
368750 USD
CY2014Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
118262463 USD
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
111723273 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
20285414 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
24493988 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21755202 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27132042 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
467698 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
122700 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
53800 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
536598 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.35
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.05
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
36.10
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.30
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0230 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5129 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q2 asmb Future Stock Based Compensation Expense Year Two
FutureStockBasedCompensationExpenseYearTwo
467914 USD
CY2014Q2 asmb Future Stock Based Compensation Expense Year Three
FutureStockBasedCompensationExpenseYearThree
613353 USD
CY2014Q2 asmb Future Stock Based Compensation Expense Year Four
FutureStockBasedCompensationExpenseYearFour
542500 USD
CY2014Q2 asmb Future Stock Based Compensation Expense Total
FutureStockBasedCompensationExpenseTotal
63500 USD
CY2014Q2 asmb Future Stock Based Compensation Expense Year Five
FutureStockBasedCompensationExpenseYearFive
1687267 USD
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
56871 USD
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
36871 USD
us-gaap Net Income Loss
NetIncomeLoss
-8474983 USD
us-gaap Net Income Loss
NetIncomeLoss
-6539190 USD
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
44000 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
44000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4679251 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4146779 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4679251 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4146779 shares
CY2014Q2 asmb Common Stock Issuable Shares
CommonStockIssuableShares
25000 shares
CY2013Q4 asmb Common Stock Issuable Shares
CommonStockIssuableShares
25000 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4069334 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3508450 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1095644 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2460174 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2546961 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1300309 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1410500 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8577727 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6616295 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4808759 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2506144 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
102744 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
77105 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-4751888 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2469273 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.43
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3679276 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4704251 shares
us-gaap Share Based Compensation
ShareBasedCompensation
979575 USD
us-gaap Share Based Compensation
ShareBasedCompensation
566335 USD
asmb Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
22190 USD
asmb Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
1177 USD
us-gaap Depreciation
Depreciation
2678 USD
us-gaap Depreciation
Depreciation
2292 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
117939 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
367803 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-160075 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1168266 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7748554 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7505455 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5166 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2589 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5166 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2589 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
20754418 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1763104 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20754418 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1763104 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13000698 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5744940 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20489219 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33489917 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
ASMB
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8688059 shares
CY2014Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
259921 USD
CY2013Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD

Files In Submission

Name View Source Status
0001144204-14-050130-index-headers.html Edgar Link pending
0001144204-14-050130-index.html Edgar Link pending
0001144204-14-050130.txt Edgar Link pending
0001144204-14-050130-xbrl.zip Edgar Link pending
asmb-20140630.xml Edgar Link completed
asmb-20140630.xsd Edgar Link pending
asmb-20140630_cal.xml Edgar Link unprocessable
asmb-20140630_def.xml Edgar Link unprocessable
asmb-20140630_lab.xml Edgar Link unprocessable
asmb-20140630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v385533_10q.htm Edgar Link pending
v385533_ex31-1.htm Edgar Link pending
v385533_ex31-2.htm Edgar Link pending
v385533_ex32-1.htm Edgar Link pending
v385533_ex32-2.htm Edgar Link pending